Biogen Names Sandrock Head of R&D As Ehlers Steps Down
October 01 2019 - 7:59AM
Dow Jones News
By Colin Kellaher
Biogen Inc. (BIIB) on Tuesday said Michael Ehlers is stepping
down as executive vice president of research and development to
pursue a new opportunity.
The Cambridge, Mass., biopharmaceutical company said Chief
Medical Officer Alfred Sandrock Jr. will assume the additional post
of executive vice president of research and development, and said
it named Alphonse Galdes executive vice president of pharmaceutical
operations and technology.
Mr. Ehlers has been head of R&D at Biogen since joining from
Pfizer Inc. (PFE) in 2016.
Mr. Sandrock, who joined Biogen in 1998, has been chief medical
officer since 2012 and a member of the company's executive
committee since 2015.
Mr. Galdes, who joining Biogen in 1995, had been serving as
senior vice president of asset development and portfolio
management.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 01, 2019 08:44 ET (12:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2024 to May 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From May 2023 to May 2024